Tales of biomaterials, molecules, and cells for repairing and treating brain dysfunction

Current Stem Cell Research and Therapy

Volumn 6, Issue 3, 2011, Pages 171-189

  Emerich, Dwaine F ^a   Orive, Gorka ^b,c,d   Borlongan, Cesar ^e  

^a InCytu Inc   (United States)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Instituto Eduardo Anitua   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Biomaterials; Central nervous system; Polymer; Stem cells

Indexed keywords

BIOMATERIAL; NANOPARTICLE; POLYMER;

ARTICLE; BRAIN DYSFUNCTION; CELL DIFFERENTIATION; CELL MIGRATION; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; BRAIN DISEASES; CHRONIC PAIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NERVE REGENERATION; NEURAL STEM CELLS; TISSUE SCAFFOLDS;

EID: 80051778751     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811796575350     Document Type: Article

References (170)

1. Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for promoting brain protection, repair, and regeneration. Nat Rev Neurosci 2009; 10: 682-692.
2. Pardridge WM. The blood-brain barrier: bottleneck in brain development. NeuroRx 2005; 3-14.
3. Pardridge WM. Drug targeting to the brain. Pharm Res 2007; 24: 1733-1744.
4. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative disorders. Int J Pharm 2006; 314: 120-126.
5. Halberstadt C, Emerich DF. (Eds.) Cellular Transplants: From Lab to Clinic. Academic Press: New York 2007.
6. Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol 2005; 63: 301-306.
7. Zhong Y, Bellamkonda R. Biomaterials for the central nervous system. J Roy Soc Interface 2008; 5: 957-975.
8. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007; 6: 521-532.
9. Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol 2005; 30: 57-70.
10. Neuwelt E, Abbott NJ, Abrey L, et al. Strategies to advance translational research into brain barriers. Lancet Oncol 2008; 7: 84-96.
11. Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-4967.
12. Weinstein JN, Blumenthal R, Sharrow SO, Henkart PA. Antibody mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. Biochem Biophys Acta 1978; 509: 272-288.
13. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drugcarrying immunoliposomes as anticancer agents. Clin Cancer Res 2002; 8: 955-956.
14. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the difficulties. Pharmacol Ther 2004; 104: 29-45.
15. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology strategies for drug delivery to the brain. Curr Topics Med Chem 2009; 9: 182-196.
16. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8: 1112-1120.
17. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005; 2: 99-107.
18. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15: 215-220.
19. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001; 90: 667-680.
20. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharmacol Sci 2003; 6: 252-273.
21. Pardridge WM, Boado RJ, Black KL, Cancilla PA. Blood-brain barrier and new approaches to brain drug delivery. West J Med 1992; 156: 281-286.
22. Tiwri SB, Amuji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006; 3: 219-232.
23. Tokes ZA, St Peteri AK, Todd JA. Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier. Brain Res 1980; 188: 282-286.
24. Schackert G, Fan D, Nayar R, Fidler I. Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. J Sel Cancer Ther 1989; 5: 73-79.
25. Chekhonin VP, Zhirkov YA, Gurina OI, et al. Polyethyleneglycolated immunoliposomes specific for astrocytes. Dokl Biochem Biophys 2003; 391: 236-239.
26. Onodera H, Takada G, Tada K, Desnick RJ. Microautoradiographic study on the tissue localization of liposome-entrapped or unentrapped 3H-labeled beta-galactosidase injected into rats. Tohoku J Exp Med 1993; 140: 1-13.
27. Postmes TJ, Hukkelhoven M, van den Bogaard AE, Halders SG, Coenegracht J. Passage through the blood-brain barrier of thyrotropin- releasing hormone encapsulated in liposomes. J Pharm Pharmacol 1980; 32: 722-724.
28. Loeb C, Benassi E, Besio G, Maffini M, Tanganelli P. Liposomeentrapped GABA modifies behavioral and electrographic changes of penicillin-induced epileptic activity. Neurology 1982; 32: 1234-1238.
29. Mori N, Kurokouchi A, Osonoe K, et al. Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res 1995; 703: 184-190.
30. Chapat S, Frey V, Claperon N, et al. Efficiency of liposomal ATP in cerebral ischemia: bioavailability features. Brain Res Bull 1991; 26: 339-342.
31. Sinha J, Das N, Basu MK. Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biomed Pharmacother 2001; 55: 264-271.
32. Fresta M, Puglisi G, Di Giacomo C, Russo A. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J Pharm Pharmacol 1994; 46: 974-981.
33. Imaizumi S, Woolworth V, Fishman RA, Chan PH. Liposomeentrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke 1990; 2: 1312-7.
34. Flanagan TR, Emerich DF, Winn SR (Eds) Methods in Neuroscience, vol. 21: Providing Therapeutic Access to the Brain: New Approaches. Academic Press, 1994.
35. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 2001; 98: 12754-12759.
36. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002; 10: 73-79.
37. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14: 1-12.
38. Jiang C, Koyabu N, Yonemitsu Y, et al. In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. Hum Gene Ther 2003; 14: 1181-1191.
39. Kakinuma K, Tanaka R, Takahashi H, Sekihara Y, Watanabe M, Kuroki M. Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int J Hypertherm 1996; 12: 157-165.
40. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. RGDanchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003; 261: 43-55.
41. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
42. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate- 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-416.
43. Schroder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996; 710: 121-124.
44. Ramge P, Kreuter J, Lemmer B. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles. Chronobiol Int 1999; 16: 767-777.
45. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674; 171-174.
46. Kreuter J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J Nanosci Nanotechnol 2004; 4: 484-488.
47. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Delivery of loperamide across the blood-brain barrier with polysorbate 80- coated polybutylcyanoacrylate nanoparticles. J Control Rel 1997; 49: 81-87.
48. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998; 15: 67-74.
49. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325-328.
50. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998; 87: 1305-1307.
51. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. J Pharm Res 1999; 16: 1564-1569.
52. Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J Control Release 2009; 135: 119-126.
53. Gu H, Long D, Song C, Li X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci Lett 2009; 453: 204-209.
54. Péan JM, Menei P, Morel O, Montero-Menei CN, Benoit JP. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials 2000; 20: 2097-2101.
55. Menei P, Pean JM, Nerrière-Daguin V, Jollivet C, Brachet P, Benoit JP. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exper Neurol 2000; 161: 259-272.
56. Mc Rae A, Dahlstrom A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism. Neurochem Int 1994; 25: 27-33.
57. Schubert D, Dargusch R, Raitano J, Chan SW. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys 2006; 342: 86-91.
58. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Del Rev 2007; 59: 454-477.
59. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain drug targeting. J Control Rel 2008; 127: 97-109.
60. Brioschi A, Zenga F, Zara GP, Gasco MR, Ducati A, Mauro A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res 2007; 29: 324-330.
61. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008; 25: 2262-2271.
62. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood brain barrier. Biomaterials 2008; 29: 1509-1517.
63. de Vos P, Bucko M, Gemeiner P, et al. Ansorge-Schumacher MB Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009; 30: 2559-2570.
64. Orive G, Hernández RM, Gascón AR, Calafiore R, Chang TM, De Vos P, Hortelano G, Hunkeler D, Lacík I, Shapiro AM, Pedraz JL. Cell encapsulation: promise and progress. Nat Med 2003; 9: 104-107.
65. Czech KA, Sagen J. Update on cellular transplantation into the rat CNS as a novel therapy for chronic pain. Prog Neurobiol 1995; 46: 507-515.
66. Sajadi A, Bensadoun JC, Schneider BL, Lo Bianco C, Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis 2006; 22: 119-129.
67. Yasuhara T, Shingo T, Muraoka K, et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factorproducing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg 2005; 102: 80-89.
68. Emerich DF, Winn SR, Chen E-Y, et al. Protective effects of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386: 395-399.
69. Winn SR, Hammang JP, Emerich DF, Lee A, Palmiter RD, Baetge EE. Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc Natl Acad Sci USA 1994; 91: 23-8.
70. Tan SA, Déglon N, Zurn AD, et al. Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transpl 1996; 5: 577-587.
71. Visted T, Lund-Johansen M. Progress and challenges for cell encapsulation in brain tumor therapy. Expert Opin Biol Ther 2003; 3: 551-561.
72. Emerich DF, Borlongan CV. Potential of Choroid Plexus Epithelial Cell Grafts for Neuroprotection in Huntington's Disease: What Remains Before Considering Clinical Trials. Neurotox Res 2009; 15: 205-211.
73. Borlongan CV, Masuda T, Walker TA, et al. Nanotechnology as an adjunct tool for transplanting engineered cells and tissues. Curr Mol Med 2007; 7: 609-618.
74. Emerich DF, Thanos CG, Goddard M, et al. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis 2006; 23: 471-480.
75. Bloch J, Bachoud-Lévi AC, Déglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15: 968-975.
76. Aebischer P, Schluep M, Déglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2: 696-699.
77. Zurn AD, Henry H, Schluep M, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically-engineered xenogeneic cells. Cell Transpl 2000; 9: 471-484.
78. Sieving A, Caruso C, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants Proc Natl Acad Sci USA 2006; 103: 3896-901.
79. NsGene, inc. press release. www.nsgene.dk; July 4, 2008.
80. Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: Pharmacokinetics and acute-phase response in rat. Ann Neurol 1994; 35: 151-63.
81. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rhCNTF) in patients with amytrophic lateral sclerosis: Relationship to parameters of the acute phase response. Clin Neuropharmacol 1995; 18: 500-14.
82. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 1995; 18: 515-32.
83. Sagen J. Cellular Transplantation for intractable pain. Adv Pharmacol 1998; 42: 579-82.
84. Aebischer P, Buchser E, Joseph JM, et al. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression - a preliminary report. Transplantation 1994; 58: 1275-7.
85. Buchser E, Goddard M, Heyd B, et al. Immunoisolated xenogeneic chromaffin cell therapy for chronic pain. Initial clinical experience. Anesthesiology 1996; 5: 1005-12.
86. CytoTherapeutics press release, Providence, RI, June 24, 1999.
87. Bachoud-Levi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000; 11: 1723-9.
88. Legler JM, Gloeckler Ries LA, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999; 91: 1382-90.
89. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995; 345: 1008-12.
90. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88.
91. Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007; 13: 3637-41.
92. Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002; 60: 53-9.
93. Vukelja SJ, Anthony SP, Arseneau JC, et al. Phase 1 study of escalating- dose OncoGel (ReGel/paclitaxel) depot injection, a controlled- release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007; 18: 283-9.
94. Allard E, Passirani C, Benoit JP. Convention-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009; 30: 2302-18.
95. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 2008; 108; 989-98.
96. Voges J, Reszka R, Gossmann A, et al. Imaging guided convection- enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003; 54: 479-87.
97. Ferrari M. Cancer nanotechnology opportunities and challenges. Nat Rev Cancer 2005; 5: 161-71.
98. Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 33: 4947-67.
99. Dobson J. Magnetic nanoparticles for drug delivery. Drug Devel Res 2006; 67: 55-60.
100. Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic J, Russell DA. Intracellular photodynamic therapy with photosensitizer- nanoparticle conjugates: cancer therapy using a ''Trojan horse''. Photochem Photobiol Sci 2006; 5: 727-34.
101. Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008; 16: 73-8.
102. Doi A, Kawabata S, Iida K, et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 2008; 87: 287-94.
103. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
104. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564-9.
105. Gelperina S, Smirnova Z, Skidan JK. Proceedings of 3rd World Meeting APV/APGI: Berlin. 2000, pp. 441-2.
106. Zara GR, Cavalli R, Bargoni A, Fundarò A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002; 10: 327-35.
107. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002; 91: 1324-33.
108. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-- tissue distribution. Pharm Res 2001; 43: 497-502.
109. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel 2004; 99: 259-69.
110. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759-67.
111. Kuroda J, Kuratsu J, Yasunaga M, Koga MY, Saito Y. Matsumura, Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 2009; 124: 2505-11.
112. Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. Am J Neuroradiol 2002; 23: 510-9.
113. Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000; 214: 568-74.
114. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009; 29: 853-60.
115. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. Am J Neuroradiol 2005; 26: 2290-300.
116. Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004; 30: 456-71.
117. Britz GW, Ghatan S, Spence AM, Berger BS. Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model. J Neurooncol 2002; 56: 227-32.
118. Ozawa T, Britz GW, Kinder DH, et al. Bromophenol blue staining of tumors in a rat glioma model. Neurosurgery 2005; 57: 1041-7.
119. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63: 8122-5.
120. Veiseh O, Sun A, Gunn J, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005; 5: 1003-8.
121. Tréhin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 2006; 8: 302-11.
122. Remsen LG, McCormick CI, Roman-Goldstein S, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. Am J Neuroradiol 1996; 17: 411-8.
123. Veiseh O, Sun C, Fang C, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009; 69: 6200-7.
124. Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12: 6677-86.
125. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005; 21: 8858-64.
126. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2006; 2: 785-92.
127. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 2005; 16: 63-72.
128. Jackson H, Muhammad O, Daneshvar H, et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 2007; 60: 524-9.
129. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22: 969-76.
130. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Rel 2007; 119: 236-44.
131. Koo YE, Fan W, Hah WH, et al. Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl Opt 2007; 46: 1924-30.
132. Ou Z, Wu B, Xing D, Zhou F, Wang H, Tang Y. Functional singlewalled carbon nanotubes based on an integrin alpha v beta 3 monoclonal antibody for highly efficient cancer cell targeting. Nanotechnology 2009; 20(10): 105102.
133. Xiang L, Yuan Y, Xing D, Ou Z, Yang S, Zhou F. Photoacoustic molecular imaging with antibody-functionalized single-walled carbon nanotubes for early diagnosis of tumor. J Biomed Opt 2009; 14(2): 021008.
134. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 1999; 19: 8182-98.
135. Geller HM, Fawcett JW. Building a bridge: engineering spinal cord repair. Exper Neurol 2002; 174: 125-36.
136. Nomura H, Tator CH, Shoichet MS. Bioengineered strategies for spinal cord repair. J Neurotrauma 2006; 23: 496-507.
137. Piantino J, Burdick JA, Goldberg D, Langer R, Benowitz LI. An injectable, biodegradable hydrogel for trophic factor delivery enhances axonal rewiring and improves performance after spinal cord injury. Exper Neurol 2006; 201: 359-67.
138. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Synthetic hydrogel guidance channels facilitate regeneration of adult rat brainstem motor axons after complete spinal cord transection. J Neurotrauma 2004; 21: 789-804.
139. Park KI, Teng YD, Snyder EY. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 2002; 20: 1091-3.
140. Tate MC, Shear DA, Hoffman SW, Stein DG, Archer DR, LaPlaca MC. Fibronectin promotes survival and migration of primary neural stem cells transplanted into the traumatically injured mouse brain. Cell Transpl 2002; 11: 283-95.
141. Tate CC, Shear DA, Tate MC, Archer DR, Stein DG, Laplaca MC. Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. J Tiss Engin Regen Med 2009; 3: 208-17.
142. Lee YL, Mooney DJ. Cell-Interactive Polymers for Tissue Engineering. Fibers and Polymers 2001; 2: 51-7.
143. Wong DY, Krebsbach PH, Hollister SJ. Brain cortex regeneration affected by scaffold architectures. J Neurosurg 2008; 109: 715-22.
144. Wong DY, Hollister SJ, Krebsbach PH, Nosrat C. Poly(epsiloncaprolactone) and poly (L-lactic-co-glycolic acid) degradable polymer sponges attenuate astrocyte response and lesion growth in acute traumatic brain injury. Tissue Engineer 2007; 13: 2515-23.
145. Zhang H, Kamiya T, Hayashi T, et al. Gelatin-siloxane hybrid scaffolds with vascular endothelial growth factor induces brain tissue regeneration. Curr Neurovasc Res 2008; 5: 112-7.
146. Potter W, Kalil RE, Kao WJ. Biomimetic material systems for neural progenitor cell-based therapy. Front Biosci 2008; 13: 806-21.
147. Teixeira A, Duckworth JK, Hermanson O. Getting the right stuff: Controlling neural stem cell state and fate in vivo and in vitro with biomaterials. Cell Res 2007; 17: 56-61.
148. Webb K, Budko E, Neuberger TJ, Chen S, Schachner M, Tresco PA. Substrate-bound human recombinant L1 selectively promotes neuronal attachment and outgrowth in the presence of astrocytes and fibroblasts. Biomaterials 2001; 22: 1017-28.
149. Norman JJ, Desai TA. Methods for fabrication of nanoscale topography for tissue engineering scaffolds. Annals of Biomed Eng 2006; 34: 89-101.
150. Yamada KM, Olden K. Fibronectins-adhesive glycoproteins of cell surface and blood. Nature 1978; 275: 179-84.
151. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517-8.
152. Woerly S, Pinet E, de Robertis L, Van Diep D. Bousmina M. Spinal cord repair with PHPMA hydrogel containing RGD peptides (NeurogelTM). Biomaterials 2001; 20: 2213-21.
153. Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994; 269: 24756-61.
154. Smyth N, Vatansever HS, Murray P, et al. Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J Cell Biol 1999; 144: 151-60.
155. Graf J, Ogle RC, Robey FA, et al. A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor. Biochemistry 1987; 26: 6896-900.
156. Jucker M, Kleinman HK, Ingram DK. Fetal rat septal cells adhere to and extend processes on basement membrane, laminin, and a synthetic peptide from the laminin A chain sequence. J Neurosci Res 1991; 28: 507-17.
157. Yu TT, Shoichet MS. Guided cell adhesion and outgrowth in peptide- modified channels for neural tissue engineering. Biomaterials 2005; 26: 1507-14.
158. Itoh S, Suzuki M, Yamaguchi I, et al. Development of a nerve scaffold using a tendon chitosan tube. Artificial Organs 2003; 27: 1079-88.
159. Ellis-Behnke RG, Liang YX, You SW, et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 2006; 103: 5054-9.
160. Nisbet DR, Pattanawong S, Ritchie NE, et al. Interaction of embryonic cortical neurons on nanofibrous scaffolds for neural tissue engineering. J Neural Engineer 2007; 4: 35-41.
161. Silva GA, Czeisler C, Niece KL, et al. Selective differentiation of neural progenitor cells by high epitope density nanofibers. Science 2004; 303: 1352-5.
162. Bhang SH, Lim JS, Choi CY, Kwon YK, Kim BS. The behavior of neural stem cells on biodegradable synthetic polymers. J Biomater Sci Polym Edin 2007; 18: 223-39.
163. Brännvall K, Bergman K, Wallenquist U, et al. Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan matrix. J Neurosci Res 2007; 85: 2138-46.
164. Hung CH, Lin YL, Young TH. The effect of chitosan and PVDF substrates on the behavior of embryonic rat cerebral cortical stem cells. Biomaterials 2006; 27: 4461-9.
165. Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. Curr Drug Targets 2005; 6: 111-26.
166. Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-eldor J, Langer R. Differentiation of human embryonic stem cells on threedimensional polymer scaffolds. Proc Natl Acad Sci USA 2003; 100: 12741-6.
167. Willerth SM, Arendas KJ, Gottlieb DI, Sakiyama Elbert SE. Optimization of fibrin scaffolds for differentiation of murine embryonic stem cells into neural lineage cells. Biomaterials 2006; 27: 5990-6003.
168. Young TH, Hung CH. Behavior of embryonic rat cerebral cortical stem cells on the PVA and EVAL substrates. Biomaterials 2005; 26: 4291-9.
169. Bible E, Chau DYS, Alexander MR, Price J, Shakesheff KM, Modo M. The support of neural stem cells transplanted into strokeinduced brain cavities by PLGA particles. Biomaterials 2009; 30: 2985-94.
170. Mahoney MJ, Saltzman WM. Transplantation of brain cells assembled around a programmable synthetic microenvironment. Nat Biotechnol 2001; 19: 934-9.